HUP0302240A2 - Humán receptorfehérjék, ezekkel kapcsolatos reagensek és eljárások - Google Patents

Humán receptorfehérjék, ezekkel kapcsolatos reagensek és eljárások

Info

Publication number
HUP0302240A2
HUP0302240A2 HU0302240A HUP0302240A HUP0302240A2 HU P0302240 A2 HUP0302240 A2 HU P0302240A2 HU 0302240 A HU0302240 A HU 0302240A HU P0302240 A HUP0302240 A HU P0302240A HU P0302240 A2 HUP0302240 A2 HU P0302240A2
Authority
HU
Hungary
Prior art keywords
methods
cells
mammalian
dtlr2
development
Prior art date
Application number
HU0302240A
Other languages
English (en)
Inventor
J. Fernando Bazan
Gerard T. Hardiman
Stephen W. K. Ho
Robert A. Kastelein
Yong-Jun Liu
Fernando L. Rock
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0302240A2 publication Critical patent/HUP0302240A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02D—CONTROLLING COMBUSTION ENGINES
    • F02D11/00—Arrangements for, or adaptations to, non-automatic engine control initiation means, e.g. operator initiated
    • F02D11/06—Arrangements for, or adaptations to, non-automatic engine control initiation means, e.g. operator initiated characterised by non-mechanical control linkages, e.g. fluid control linkages or by control linkages with power drive or assistance
    • F02D11/10—Arrangements for, or adaptations to, non-automatic engine control initiation means, e.g. operator initiated characterised by non-mechanical control linkages, e.g. fluid control linkages or by control linkages with power drive or assistance of the electric type
    • F02D11/106—Detection of demand or actuation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02D—CONTROLLING COMBUSTION ENGINES
    • F02D11/00—Arrangements for, or adaptations to, non-automatic engine control initiation means, e.g. operator initiated
    • F02D11/06—Arrangements for, or adaptations to, non-automatic engine control initiation means, e.g. operator initiated characterised by non-mechanical control linkages, e.g. fluid control linkages or by control linkages with power drive or assistance
    • F02D11/10—Arrangements for, or adaptations to, non-automatic engine control initiation means, e.g. operator initiated characterised by non-mechanical control linkages, e.g. fluid control linkages or by control linkages with power drive or assistance of the electric type
    • F02D11/107—Safety-related aspects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Veterinary Medicine (AREA)
  • Combustion & Propulsion (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát képezi kilenc új, emlősszervezetből származó,például humán Toll-receptorszerű molekuláris struktúra, melyekjelölése DTLR2-10, valamint bio:Lógiai aktivitásaik. A találmánytárgyát képezik az ilyen fehérjéket vagy polipeptideket tartalmazófúziós fehérjék, kódoló nukleinsavak, a nukleinsavat tartalmazóexpressziós vektor és gazdasejt, valamint előállításukra szolgálóeljárások. A találmány szerinti vegyületek emlős fiziológiát, példáulmorfogenezist és/vagy az immunrendszer funkcióját képesekbefolyásolni. Ezek az anyagok diagnosztikai és terápiás eljárásokbanalkalmazhatók olyan degeneratív vagy abnormális állapot kezelésében,amelyek közvetlenül vagy közvetve például az immunrendszer és/vagyhematopoetikus sejtek fejlődésével, differenciálódásával vagyfunkciójával kapcsolatosak. A találmány tárgyát képezi továbbá eljárássejtek fiziológiájának vagy fejlődésének modulálására, amelyben asejteket emlősszervezetből származó DTLR2-10 agonistával vagyantagonistával érintkeztetnek. Ó
HU0302240A 2000-05-25 2001-05-23 Humán receptorfehérjék, ezekkel kapcsolatos reagensek és eljárások HUP0302240A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20755800P 2000-05-25 2000-05-25
PCT/US2001/016766 WO2001090151A2 (en) 2000-05-25 2001-05-23 Human receptor proteins; related reagents and methods

Publications (1)

Publication Number Publication Date
HUP0302240A2 true HUP0302240A2 (hu) 2003-10-28

Family

ID=22771074

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302240A HUP0302240A2 (hu) 2000-05-25 2001-05-23 Humán receptorfehérjék, ezekkel kapcsolatos reagensek és eljárások

Country Status (13)

Country Link
EP (4) EP1283849A2 (hu)
JP (1) JP2003533996A (hu)
KR (1) KR100907356B1 (hu)
CN (2) CN1222539C (hu)
AU (3) AU6488901A (hu)
CA (1) CA2410082A1 (hu)
HK (1) HK1049017A1 (hu)
HU (1) HUP0302240A2 (hu)
IL (2) IL152725A0 (hu)
MX (1) MXPA02011618A (hu)
NZ (2) NZ522327A (hu)
WO (1) WO2001090151A2 (hu)
ZA (1) ZA200208856B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
JP2002034565A (ja) * 2000-07-19 2002-02-05 Japan Science & Technology Corp 細菌ｄｎａを特異的に認識する受容体タンパク質
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
CA2461315A1 (en) * 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CN1878793A (zh) 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
DK1773872T3 (en) * 2004-05-21 2017-05-08 Uab Res Found VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
WO2006025995A2 (en) * 2004-07-27 2006-03-09 The Regents Of The University Of California Compositions and methods using md-2 mutants and chimeric proteins
EP1657257A1 (en) * 2004-11-11 2006-05-17 Klinikum der Universität Regensburg Recombinant TLR-MD-2 fusion proteins
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
CN101415438B (zh) * 2004-11-30 2013-03-27 森托科尔公司 Toll样受体3拮抗剂、方法和用途
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
US7700728B2 (en) 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
CA2710760C (en) * 2007-12-26 2017-05-16 Centocor Ortho Biotech Inc. Cynomolgus toll-like receptor 3
JP6131046B2 (ja) 2010-01-27 2017-05-17 武田薬品工業株式会社 抗癌剤により誘発される末梢神経障害を抑制する化合物
AU2012262014B2 (en) 2011-06-01 2016-07-14 Janus Biotherapeutics, Inc. Novel immune system modulators
US9353115B2 (en) 2011-06-01 2016-05-31 Janus Biotherapeutics, Inc. Immune system modulators
AU2012318694B2 (en) 2011-10-04 2016-12-22 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
SG11202010939WA (en) 2018-05-31 2020-12-30 Daiichi Sankyo Co Ltd Anti-human tlr7 antibody
KR102265432B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4215149A (en) 1978-11-17 1980-07-29 Standard Brands Incorporated Process for improving the palatability of pet food
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
DK0980429T3 (da) * 1997-05-07 2007-04-10 Schering Corp Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder
AU1070399A (en) * 1997-10-17 1999-05-10 Genentech Inc. Human toll homologues
JP2000128900A (ja) * 1998-10-26 2000-05-09 Japan Science & Technology Corp 新規トル様（Ｔｏｌｌ−ｌｉｋｅ）レセプター及びその遺伝子
GB0001704D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
CA2401076A1 (en) * 2000-02-24 2001-08-30 Incyte Genomics, Inc. Molecules for disease detection and treatment

Also Published As

Publication number Publication date
IL192111A0 (en) 2008-12-29
EP1433792A2 (en) 2004-06-30
WO2001090151A2 (en) 2001-11-29
NZ534666A (en) 2006-01-27
CN1222539C (zh) 2005-10-12
IL152725A0 (en) 2003-06-24
AU6488901A (en) 2001-12-03
MXPA02011618A (es) 2003-03-10
AU2009200539A1 (en) 2009-03-05
EP1714980A1 (en) 2006-10-25
AU2006222684A1 (en) 2006-10-19
EP1283849A2 (en) 2003-02-19
JP2003533996A (ja) 2003-11-18
CN1721443A (zh) 2006-01-18
EP1908837A2 (en) 2008-04-09
WO2001090151A3 (en) 2002-10-17
KR20030003761A (ko) 2003-01-10
NZ522327A (en) 2004-09-24
EP1433792A8 (en) 2004-10-06
CN1444602A (zh) 2003-09-24
EP1433792A3 (en) 2004-11-17
CA2410082A1 (en) 2001-11-29
ZA200208856B (en) 2004-03-24
EP1908837A3 (en) 2008-06-11
KR100907356B1 (ko) 2009-07-10
AU2006222684B2 (en) 2008-12-11
HK1049017A1 (zh) 2003-04-25

Similar Documents

Publication Publication Date Title
HUP0302240A2 (hu) Humán receptorfehérjék, ezekkel kapcsolatos reagensek és eljárások
Yoshikawa et al. Synthetic protein condensates that inducibly recruit and release protein activity in living cells
Azambuja et al. The dawn of metal-oxo clusters as artificial proteases: From discovery to the present and beyond
Gibbs et al. Biochemical properties of normal and oncogenic ras p21
Castro-Chavez The rules of variation: amino acid exchange according to the rotating circular genetic code
Mellgren et al. Intracellular calcium-dependent proteolysis
Zahid et al. Cardiac targeting peptide, a novel cardiac vector: studies in bio-distribution, imaging application, and mechanism of transduction
Staros et al. Cross-linking and chymotryptic digestion of the extractoplasmic domain of the anion exchange channel in intact human erythrocytes
NZ531570A (en) DNA sequences for human angiogenesis genes
CN101583374B (zh) 抗可卡因组合物和治疗
DE69808743T2 (de) Netrinrezeptoren
EP3360958A1 (en) Thermostable blunt-end ligase and methods of use
Huang et al. Novel techniques and future perspective for investigating critical-size bone defects
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
CN102858965A (zh) 纯化和利用来自超嗜热菌的无机焦磷酸酶的系统和方法
DE69528379D1 (de) Paraoxonase aus serum
Rochu et al. Multiple advantages of capillary zone electrophoresis for exploring protein conformational stability
ATE432346T1 (de) Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
Maruyama et al. Hemoglobins of the tadpole of the bullfrog, Rana catesbeiana. Amino acid sequence of the alpha chain of a major component.
KR20170074503A (ko) 세포 배양 어세이를 이용한 약물 평가 방법
CN103834740B (zh) 一种检测细胞凋亡的hsv1-tk分子影像探针
WO2001048161A3 (en) Human heparanase-related polypeptide and nucleic acid
Chen et al. Eg5 inhibitors have contrasting effects on microtubule stability and spindle integrity depending on their modes of action
Colgan Cell'Cell Interactions: Methods and Protocols
WO1999018203A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND cDNAs ENCODING THESE PROTEINS

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees